迪哲醫藥(688192.SH):2022年度預虧7.4億元左右
格隆匯1月20日丨迪哲醫藥(688192.SH)公佈,公司預計2022年度歸屬於母公司所有者的淨虧損7.4億元左右,與上年同期相比,增加虧損7000萬元左右,同比虧損增加10%左右。公司預計2022年度歸屬於母公司所有者的扣除非經常性損益後的淨虧損7.9億元左右,與上年同期相比,增加虧損1.1億元左右,同比虧損增加16%左右。
公司預計2022年研發費用為6.64億元左右,與上年同期相比,增加7600萬元左右,同比增長13%左右。
報吿期內,公司所有在研產品均處於研發階段,尚未開展商業化銷售,公司產品尚未實現銷售收入。報吿期內,公司持續投入資金用於推出新產品進入臨牀前研究及臨牀試驗;隨着研發進度的推進,產品管線中的部分產品處於全球註冊臨牀階段,需進行較大規模的研發投入,導致公司研發費用持續增大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.